Table IV.
TEAE summary during double-blind period in safety population
| TEAE | Part 1 |
Part 2 |
||||
|---|---|---|---|---|---|---|
| Telazorlimab |
Placebo (n = 80) | Telazorlimab 600 mg q2w (n = 75) | Placebo (n = 74) | |||
| 300 mg q2w (n = 76) | 300 mg q4w (n = 78) | 75 mg q4w (n = 77) | ||||
| Any TEAE | 52 (68.4) | 45 (57.7) | 56 (72.7) | 58 (72.5) | 49 (65.3) | 37 (50.0) |
| Treatment discontinuation due to TEAE | 1 (1.3) | 2 (2.6) | 1 (1.3) | 3 (3.8) | 0 | 2 (2.7) |
| Serious TEAE | 3 (3.9) | 2 (2.6) | 2 (2.6) | 1 (1.3) | 1 (1.3) | 0 |
| TEAE > 5% in any treatment group | ||||||
| Dermatitis atopic | 14 (18.4) | 19 (24.4) | 17 (22.1) | 18 (22.5) | 13 (17.3) | 12 (16.2) |
| Nasopharyngitis | 3 (3.9) | 9 (11.5) | 7 (9.1) | 7 (8.8) | 6 (8.0) | 7 (9.5) |
| Upper respiratory tract infection | 6 (7.9) | 4 (5.1) | 7 (9.1) | 4 (5.0) | 4 (5.3) | 5 (6.8) |
| Headache | 6 (7.9) | 5 (6.4) | 2 (2.6) | 8 (10.0) | 5 (6.7) | 5 (6.8) |
| Urinary tract infection | 2 (2.6) | 2 (2.6) | 4 (5.2) | 4 (5.0) | 2 (2.7) | 2 (2.7) |
| Pruritus | 0 | 1 (1.3) | 4 (5.2) | 1 (1.3) | 1 (1.3) | 2 (2.7) |
| Fatigue | 0 | 4 (5.1) | 1 (1.3) | 0 | 1 (1.3) | 0 |
Data are presented as nos. (%). q2w, Every 2 weeks; q4w, every 4 weeks.